Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Pregnancy complications may predict heart disease: major study continues

NCT ID NCT05472597

Knowledge-focused Sponsor: RTI International Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 02, 2026 · Updated 2 times

Summary

This study follows over 4,000 women who were tracked during their first pregnancy to see how pregnancy complications like high blood pressure or diabetes relate to future heart disease. Researchers will check for conditions like high blood pressure, diabetes, and obesity over time. The goal is to better predict and prevent heart disease in women. Participants do not receive any treatment—this is an observational study.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 4,048 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2022

Expected to finish

Jan 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The original nuMoM2b cohort consisted of an ethnically and racially diverse group of pregnant women aged 13 or over who had not had a pregnancy lasting 20 weeks or more, enrolled during the first trimester. Overall, 62% of the nuMoM2b-HHS participants are non-Hispanic white, 14% non-Hispanic black, 16% Hispanic, and 8% mixed race or other. The socio-demographics on the nuMoM2b-HHS participants vary substantially by clinical site, contributing to a rich degree of diversity within the cohort.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria for nuMoM2b-HHS2 interval contact (telephone interview or web-based self-administered survey): * Completed one or more interval contacts during the nuMoM2b Heart Health Study. * Able to speak or read in English or Spanish. Exclusion Criteria for nuMoM2b-HHS2 interval contact (telephone interview or web-based self-administered survey): * Withdrawal from study. Inclusion Criteria for nuMoM2b-HHS2 study visit: * Completed one or more interval contacts during the nuMoM2b Heart Health Study. * At least 18 years of age. * Self-report of at least 3 months postpartum from any subsequent pregnancy. * Provision of signed informed consent for the HHS2 study visit. * Able to speak or read English or Spanish. Exclusion Criteria for nuMoM2b-HHS2 study visit: * Current pregnancy. * Withdrawal from study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cardiovascular diseases are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cardiovascular disorder gestational diabetes Premature Birth Stillbirth

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cardiovascular diseases

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    14 sites. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Case Western Reserve University/The MetroHealth System

    Cleveland, Ohio, 44109, United States

  • Christiana Care Health Services

    Newark, Delaware, 19718, United States

  • Columbia University Medical Center

    New York, New York, 10032, United States

  • Hospital of the University of Pennsylvania

    Philadelphia, Pennsylvania, 19104, United States

  • Indiana University

    Indianapolis, Indiana, 46202, United States

  • Intermountain Medical Center

    Murray, Utah, 84107, United States

  • LDS Hospital

    Salt Lake City, Utah, 84143, United States

  • Magee Womens Research Institute

    Pittsburgh, Pennsylvania, 15213, United States

  • McKay-Dee Hospital

    Ogden, Utah, 84403, United States

  • Northwestern University

    Chicago, Illinois, 60611, United States

  • Pennsylvania Hospital

    Philadelphia, Pennsylvania, 19107, United States

  • University of California, Irvine Medical Center

    Orange, California, 92868, United States

  • University of Utah

    Salt Lake City, Utah, 84132, United States

  • Utah Valley Hospital

    Provo, Utah, 84604, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.